TOVX Stock - Theriva Biologics, Inc.
Unlock GoAI Insights for TOVX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-26,346,000 | $-21,431,000 | $-21,581,000 | $-14,274,000 | $-10,160,000 |
| Net Income | $-25,653,000 | $-18,349,000 | $-19,685,000 | $-14,267,000 | $-10,043,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-19.03 | $-28.49 | $-32.66 | $-1.90 | $-6.60 |
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
Visit WebsiteEarnings History & Surprises
TOVXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.38 | $-0.45 | -18.4% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.38 | $-1.93 | -407.9% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-4.19 | $-1.55 | +63.0% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-6.36 | $-3.30 | +48.1% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-6.25 | $-6.81 | -9.0% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-4.75 | $-5.50 | -15.8% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.34 | $-7.50 | -2105.9% | ✗ MISS |
Q1 2024 | Mar 25, 2024 | $-0.41 | $-8.00 | -1851.2% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.37 | $-4.75 | -1183.8% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.36 | $-8.50 | -2261.1% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.32 | $-7.50 | -2243.8% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $0.33 | $-9.00 | -2827.3% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.39 | $-8.25 | -2015.4% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.35 | $-0.31 | +11.4% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.30 | $-0.30 | 0.0% | = MET |
Q1 2022 | Mar 16, 2022 | $-0.30 | $-0.40 | -33.3% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.25 | $-0.20 | +20.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.20 | $-0.20 | 0.0% | = MET |
Latest News
Theriva Biologics Q3 EPS $(0.45) Beats $(1.13) Estimate
📈 PositiveTheriva Biologics Addresses Unusual NYSE Trading Activity; Confirms No New Developments Since VIRAGE Trial Data Presentation At ESMO 2025
➖ NeutralTheriva Biologics shares are trading lower after the company announced a $4 million warrant inducement agreement for the immediate exercise of warrants to purchase up to 7,360,460 of common stock at a reduced exercise price of $0.54 per share.
📉 NegativeTheriva Biologics announces warrant inducement transaction for $4M in gross proceeds
📈 PositiveTheriva Biologics Secures $4M Via Immediate Exercise Of 7.36M Warrants At $0.54/Share; Offers Investors 14.72M New Warrants At Same Price
📈 PositiveTheriva Biologics To Present VCN-12 And VCN-01 Preclinical Data At ESGCT, Highlighting Novel Antitumor Mechanism And Intracranial Feasibility For Brain Tumors
📈 PositiveTOVX stock has given up its prior gain. Theriva Biologics shares were trading higher after the company announced it cut 32% of its workforce.
➖ NeutralTheriva Biologics shares are trading higher after the company announced it cut 32% of its workforce.
📈 PositiveTheriva Biologics Cuts 32% Of Workforce In Restructuring To Focus On Cancer Drug Development And Regulatory Strategy; Expects Will Extend Its Cash Runway Into Q2 Of 2026
➖ NeutralTheriva Biologics Has Received A Notice Of Allowance For A U.S. Patent Titled "ALKALINE PHOSPHATASE FORMULATIONS (FOR THE TREATMENT OF MICROBIOME-RELATED DISEASES)".
📈 PositiveTheriva Biologics announces pricing of $7.5M public offering
➖ NeutralFrequently Asked Questions about TOVX
What is TOVX's current stock price?
What is the analyst price target for TOVX?
What sector is Theriva Biologics, Inc. in?
What is TOVX's market cap?
Does TOVX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TOVX for comparison